BioAtla Future Growth

Future criteria checks 0/6

BioAtla is forecast to grow earnings and revenue by 3% and 76.9% per annum respectively while EPS is expected to grow by 20.9% per annum.

Key information

3.0%

Earnings growth rate

20.9%

EPS growth rate

Biotechs earnings growth27.1%
Revenue growth rate76.9%
Future return on equityn/a
Analyst coverage

Low

Last updated23 Sep 2024

Recent future growth updates

Recent updates

BioAtla's FDA Fast-Tracked Drug Candidate Boosts Its Oncology Prospects, Speculative Buy

Oct 08

We're A Little Worried About BioAtla's (NASDAQ:BCAB) Cash Burn Rate

Jul 16
We're A Little Worried About BioAtla's (NASDAQ:BCAB) Cash Burn Rate

BioAtla: A Buried ADC Concern Gets Some New Life In 2024

May 02

Will BioAtla (NASDAQ:BCAB) Spend Its Cash Wisely?

Mar 14
Will BioAtla (NASDAQ:BCAB) Spend Its Cash Wisely?

Is BioAtla (NASDAQ:BCAB) In A Good Position To Deliver On Growth Plans?

Nov 05
Is BioAtla (NASDAQ:BCAB) In A Good Position To Deliver On Growth Plans?

We Think BioAtla (NASDAQ:BCAB) Needs To Drive Business Growth Carefully

Jun 27
We Think BioAtla (NASDAQ:BCAB) Needs To Drive Business Growth Carefully

Will BioAtla (NASDAQ:BCAB) Spend Its Cash Wisely?

Mar 24
Will BioAtla (NASDAQ:BCAB) Spend Its Cash Wisely?

BioAtla (NASDAQ:BCAB) Is In A Good Position To Deliver On Growth Plans

Sep 27
BioAtla (NASDAQ:BCAB) Is In A Good Position To Deliver On Growth Plans

BioAtla: Back From The Dead

Sep 23

BioAtla: Promising Signal In NSCLC, But Concerns Remain

Aug 23

BioAtla reports Q2 results

Aug 09

We're Keeping An Eye On BioAtla's (NASDAQ:BCAB) Cash Burn Rate

May 11
We're Keeping An Eye On BioAtla's (NASDAQ:BCAB) Cash Burn Rate

Companies Like BioAtla (NASDAQ:BCAB) Are In A Position To Invest In Growth

Jan 06
Companies Like BioAtla (NASDAQ:BCAB) Are In A Position To Invest In Growth

BioAtla (NASDAQ:BCAB) Is In A Good Position To Deliver On Growth Plans

Jul 24
BioAtla (NASDAQ:BCAB) Is In A Good Position To Deliver On Growth Plans

Are Insiders Buying BioAtla, Inc. (NASDAQ:BCAB) Stock?

Mar 16
Are Insiders Buying BioAtla, Inc. (NASDAQ:BCAB) Stock?

Earnings and Revenue Growth Forecasts

NasdaqGM:BCAB - Analysts future estimates and past financials data (USD Millions)
DateRevenueEarningsFree Cash FlowCash from OpAvg. No. Analysts
12/31/20265-118-134N/A4
12/31/2025N/A-103-127N/A4
12/31/2024N/A-84-76N/A4
6/30/2024N/A-105-107-107N/A
3/31/2024N/A-119-112-112N/A
12/31/2023N/A-123-104-104N/A
9/30/2023N/A-124-99-98N/A
6/30/2023N/A-117-95-95N/A
3/31/2023N/A-110-88-88N/A
12/31/2022N/A-106-91-90N/A
9/30/2022N/A-102-87-87N/A
6/30/2022N/A-99-76-76N/A
3/31/20220-101-73-72N/A
12/31/20210-95-63-62N/A
9/30/20210-79-57-55N/A
6/30/20210-68-59-58N/A
3/31/20210-44-49-48N/A
12/31/20200-27-37-36N/A
9/30/20203-22-25-24N/A
12/31/20195-29-11-10N/A
12/31/201811-28-36-35N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: BCAB is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: BCAB is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: BCAB is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: BCAB is forecast to have no revenue next year.

High Growth Revenue: BCAB is forecast to have no revenue next year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: Insufficient data to determine if BCAB's Return on Equity is forecast to be high in 3 years time


Discover growth companies